Technology
Health
Biotechnology
Soligenix
$1.029876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$1.02
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.01 (1.00%) Today
+$0.01 (0.99%) After Hours
Why Robinhood?
You can buy or sell Soligenix and other stocks, options, ETFs, and crypto commission-free!
About
Soligenix, Inc. engages in the development and commercialization of products to treat rare disease. It operates through the BioTherapeutics, and Vaccines/BioDefense segments. Read More The BioTherapeutics segment offers photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Vaccines/BioDefense segment includes active development programs for RiVax, ricin toxin vaccine candidate, OrbeShield, GI acute radiation syndrome therapeutic candidate, and SGX943, melioidosis therapeutic candidate. The company was founded in 1987 and is headquartered Princeton, NJ.
Employees
18
Headquarters
Princeton, New Jersey
Founded
1987
Market Cap
17.86M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
199.02K
High Today
$1.04
Low Today
$1.00
Open Price
$1.00
Volume
12.85K
52 Week High
$3.70
52 Week Low
$0.802
Collections
Technology
Health
Biotechnology
Therapy
2016 IPO
US
North America
News
PR NewswireMar 18
Soligenix to Present at National Institutes of Health - Commercialization Accelerator Program "FeedForward Session" in Washington, DC
PRINCETON, N.J., March 18, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that they will be presenting at the National Institutes of Health (NIH) – Commercialization Accelerator Program (CAP) "FeedForward Session" in Washington, DC on March 21, 2019. The NIH selected Soligenix's SGX942 (dusquetide) development ...
PR NewswireMar 11
Soligenix to Present at the Boston Oncology Investor Conference 2019
PRINCETON, N.J., March 11, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its Chief Scientific Officer, Oreola Donini, PhD, will deliver a corporate presentation at the Boston Oncology Investor Conference 2019 on Thursday, March 14 at 5:35 PM ET. The event will take place at 28 State Street, Boston, MA. T...
Price Paid on Robinhood
35% Lower
Right Now
52 Week Low
$0.802
Average Price Paid
$1.56
52 Week High
$3.70
Earnings
-$0.41
-$0.27
-$0.14
$0.00
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.11 per share
Actual
Expected Mar 22, Pre-Market